Saxenda vs. Farxiga
See how Saxenda and Farxiga compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Saxenda is a daily injectable GLP-1 approved for chronic weight management, while Farxiga is a once-daily pill approved for type 2 diabetes, heart failure, and chronic kidney disease.
Saxenda's most common side effects are gastrointestinal, such as nausea and diarrhea, while Farxiga's most common side effects are genital and urinary infections.
These drugs treat different core conditions and are rarely substitutes, though some patients with type 2 diabetes and obesity may end up using both.
Saxenda vs. Farxiga Drug Summary
Saxenda
Saxenda (liraglutide) is a GLP-1 receptor agonist approved for chronic weight management in adults with obesity or overweight plus a weight-related condition, and in adolescents 12 to 17 with obesity. It is injected once daily under the skin and works by reducing appetite and slowing stomach emptying. It is not approved to treat diabetes.
Farxiga
Farxiga (dapagliflozin) is an SGLT2 inhibitor taken as a once-daily oral tablet. It is approved for blood sugar control in type 2 diabetes, reducing heart failure hospitalization, treating heart failure, and slowing chronic kidney disease progression. It works by causing the kidneys to remove excess glucose through urine.
Saxenda vs. Farxiga Side Effects
Saxenda
Farxiga
Saxenda vs. Farxiga Dosage
Saxenda
Farxiga
| STAGE | DOSE | WHEN |
| Starting dose | 0.6 mg once daily | Week 1 |
| Maximum dose | 3 mg once daily | Week 5 onward |
| Dose changes | 4 increases | Every week |
| STAGE | DOSE | WHEN |
| Starting dose | 5 mg once daily | At the start |
| Maximum dose | 10 mg once daily | If needed |
| Dose changes | 1 increase | As tolerated |
Saxenda
| STAGE | DOSE | WHEN |
| Starting dose | 0.6 mg once daily | Week 1 |
| Maximum dose | 3 mg once daily | Week 5 onward |
| Dose changes | 4 increases | Every week |
Farxiga
| STAGE | DOSE | WHEN |
| Starting dose | 5 mg once daily | At the start |
| Maximum dose | 10 mg once daily | If needed |
| Dose changes | 1 increase | As tolerated |
Saxenda vs. Farxiga Indications
Saxenda
Saxenda is FDA-approved for chronic weight management in adults with obesity or overweight who also have a weight-related condition like high blood pressure or type 2 diabetes. It's also approved for adolescents aged 12 to 17 with obesity. It is not approved to treat diabetes itself, even though many people who take it also have type 2 diabetes.
Chronic weight management in adults with obesity
Weight management with a related condition like high blood pressure
Adolescents 12-17 with obesity
Not approved for treating diabetes directly
Farxiga
Farxiga is FDA-approved for blood sugar control in adults and children 10 and older with type 2 diabetes. It also carries approvals for reducing heart failure hospitalization, treating heart failure across ejection fraction types, and slowing chronic kidney disease progression. It is not approved for type 1 diabetes or diabetic ketoacidosis.
Blood sugar control in type 2 diabetes (age 10+)
Reduce risk of heart failure hospitalization
Treatment of heart failure, any ejection fraction
Slow chronic kidney disease progression
Saxenda vs. Farxiga Pros and Cons
Saxenda
Saxenda has a long track record for weight loss as one of the earliest GLP-1 drugs approved specifically for obesity, though it requires a daily injection rather than a weekly one. Insurance coverage for weight-loss indications is often limited, and many plans require prior authorization or exclude it outright.
Pros
FDA-approved specifically for chronic weight loss
Also approved for adolescents 12-17
Long track record since its 2014 approval
Cons
Requires a daily injection, not weekly
Not approved for diabetes management
Boxed warning for thyroid C-cell tumor risk
Farxiga
Farxiga covers a broad range of conditions beyond diabetes, including heart failure and chronic kidney disease, making it useful for patients with overlapping cardiovascular and renal risk. It's taken as a once-daily pill, which many people find easier than an injection, but it is not approved for weight loss.
Pros
Once-daily oral tablet, no injections
Also approved for heart failure and kidney disease
Approved use across four separate conditions
Cons
Not approved for weight management
Risk of genital and urinary tract infections
Rare risk of Fournier's gangrene and ketoacidosis
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.